Devise a strategy to incorporate emerging biologic mAbs and JAK inhibitors into treatment plans as they become available to appropriately selected patients with moderate-to-severe AD
Devise a strategy to incorporate emerging biologic mAbs and JAK inhibitors into treatment plans as they become available to appropriately selected patients with moderate-to-severe AD Strongly agree
Devise a strategy to incorporate emerging biologic mAbs and JAK inhibitors into treatment plans as they become available to appropriately selected patients with moderate-to-severe AD Agree
Devise a strategy to incorporate emerging biologic mAbs and JAK inhibitors into treatment plans as they become available to appropriately selected patients with moderate-to-severe AD Neutral
Devise a strategy to incorporate emerging biologic mAbs and JAK inhibitors into treatment plans as they become available to appropriately selected patients with moderate-to-severe AD Disagree
Devise a strategy to incorporate emerging biologic mAbs and JAK inhibitors into treatment plans as they become available to appropriately selected patients with moderate-to-severe AD Strongly disagree
Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors
Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors Strongly agree
Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors Agree
Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors Neutral
Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors Disagree
Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors Strongly disagree